Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Quantum BioPharma: Engineering the Digital Balance Sheet in Life Sciences A Vanderbilt Report View

A New Model for the Modern Issuer

BRISTOL, TN / ACCESS Newswire / October 7, 2025 / Quantum BioPharma Ltd. (NASDAQ: QNTM)(CSE:QNTM)(FRA:0K91) is quietly redrawing the boundaries of what a biotechnology company can be. The company has evolved beyond traditional R&D into a diversified enterprise-one that integrates clinical innovation, consumer health commercialization, and advanced market infrastructure.

In an era where science, data, and capital efficiency intersect, Quantum BioPharma represents a new category of public issuer: the digitally engineered life sciences company.

From Molecules to Markets

Quantum's foundation remains firmly rooted in neuroscience. Its flagship program, Lucid-MS (Lucid-21-302), is a proprietary neuroprotective compound targeting demyelination and neurodegeneration in multiple sclerosis (MS).

In collaboration with Massachusetts General Hospital, Quantum is conducting a pioneering imaging study using the PET tracer [^18F]3F4AP to monitor remyelination in vivo-a biomarker-driven approach that could redefine how neurorepair is measured and quantified.

This clinical focus demonstrates the company's disciplined scientific core. But Quantum's broader strategy reveals something more ambitious: an integrated approach to how research, data, and capital are aligned for long-term growth.

Reframing the Corporate DNA

Quantum has aligned its operations around three complementary verticals:

  • Biopharmaceutical Development - advancing Lucid-MS and related neurological compounds through translational research.

  • Consumer Health Commercialization - through Celly Nu, developer of the unbuzzd beverage, a clinically validated formulation that supports faster alcohol metabolism and cognitive recovery. Quantum retains pharmaceutical rights to the formulation and earns a royalty stream of 7 percent on sales until USD $250 million is paid, and 3 percent thereafter in perpetuity.

  • Market Access Innovation - utilizing modern trading and settlement technology to expand shareholder reach and enhance transparency for international investors.

In January 2025, Quantum's shares were approved for dual listing on Upstream, a regulated digital exchange environment designed for near-instant settlement and wider global participation. The listing underscores Quantum's commitment to accessibility, speed, and modernization within the public-market ecosystem.

A Blueprint for the Modern Capital Era

Quantum's approach goes beyond therapeutic innovation-it reflects a holistic view of how public companies can adapt to a new financial architecture. The company's leadership views its next-generation listing strategy and capital design as extensions of the same precision that drives its research pipeline: structure, clarity, and data integrity.

By modernizing how its equity trades and how investors engage with the company, Quantum is creating what The Vanderbilt Report defines as a "digital balance-sheet framework"-a structure that supports transparency, efficiency, and long-term shareholder confidence.

A Convergence of Science and Strategic Capital

Quantum BioPharma stands at the intersection of two powerful growth curves:

  • The global biotechnology market, projected to exceed $3 trillion by 2030, driven by advances in neurodegenerative and regenerative medicine.

  • The rise of next-generation market infrastructure, which is transforming how global issuers connect with investors and measure performance in real time.

By aligning these forces, Quantum BioPharma is building what The Vanderbilt Report identifies as a next-generation issuer model-one where scientific credibility, operational transparency, and shareholder connectivity define enterprise value.

The Institutional View

For investors and analysts, Quantum BioPharma represents more than a biotech story. It's a forward signal of how public companies will evolve as science, technology, and capital markets continue to merge.

From its neurorepair pipeline to its commitment to transparent, technology-enabled investor access, the company is crafting a framework that others may soon follow-a model of resilience, data-driven governance, and investor alignment in an era defined by rapid information flow.

In a market increasingly shaped by precision, speed, and trust, Quantum BioPharma is positioning itself not just as a participant-but as a prototype.

See the full report at The Vanderbilt Report

About The Vanderbilt Report

The Vanderbilt Report was founded with a clear mission - to redefine how a new generation engages with Wall Street. We deliver trusted market intelligence, founder insights, and institutional-grade analysis designed for today's dynamic investment landscape. By blending traditional reporting with real-time data and narrative-driven coverage, The Vanderbilt Report provides clarity and credibility for investors, funds, and public companies navigating the modern markets.

Compliance Note:
This announcement is based on Quantum BioPharma Ltd.'s public filings and official disclosures, including its clinical updates, market announcements, and investor communications. It does not constitute investment advice, a solicitation, or a recommendation to buy or sell securities.

CONTACT
Vanderbilt Report Media Relations
Kristen Owens
info@vanderbiltreport.com

SOURCE: Quantum BioPharma Ltd



View the original press release on ACCESS Newswire

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  213.04
+0.00 (0.00%)
AAPL  252.29
+0.00 (0.00%)
AMD  233.08
+0.00 (0.00%)
BAC  51.28
+0.00 (0.00%)
GOOG  253.79
+0.00 (0.00%)
META  716.91
+0.00 (0.00%)
MSFT  513.58
+0.00 (0.00%)
NVDA  183.16
-0.06 (-0.03%)
ORCL  291.31
+0.00 (0.00%)
TSLA  439.31
+0.00 (0.00%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.